MEDP:NSD-Medpace Holdings Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 361.94

Change

+1.13 (+0.31)%

Market Cap

USD 9.93B

Volume

0.33M

Analyst Target

USD 118.40
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+3.71 (+0.87%)

USD 34.17B
ILMN Illumina Inc

-1.45 (-0.98%)

USD 23.86B
ICLR ICON PLC

-8.37 (-3.94%)

USD 18.82B
NTRA Natera Inc

+25.85 (+19.13%)

USD 15.36B
EXAS EXACT Sciences Corporation

+0.57 (+1.14%)

USD 13.02B
RDNT RadNet Inc

-1.03 (-1.23%)

USD 5.00B
SHC Sotera Health Co

-0.22 (-1.42%)

USD 4.49B
GH Guardant Health Inc

+1.88 (+6.32%)

USD 3.53B
NEOG Neogen Corporation

-0.16 (-1.04%)

USD 3.13B
TWST Twist Bioscience Corp

-2.77 (-6.12%)

USD 2.66B

ETFs Containing MEDP

UIQI:F UBS (Irl) Fund Solutions .. 96.30 % 0.00 %

-0.42 (1.77%)

USD 0.31B
UIQI:XETRA UBS (Irl) Fund Solutions .. 96.30 % 0.00 %

-0.50 (1.77%)

USD 0.31B
AJEUAS:SW UBS (Irl) Fund Solutions .. 96.30 % 0.00 %

+2.38 (+1.77%)

N/A
LCPE:LSE Ossiam Shiller Barclays C.. 7.75 % 0.00 %

+40.00 (+1.77%)

USD 0.17B
DXSH:XETRA Xtrackers - Stoxx Europe .. 4.82 % 0.00 %

-1.46 (1.77%)

USD 0.03B
L6EW:LSE Ossiam Stoxx Europe 600 E.. 4.65 % 0.00 %

-54.00 (1.77%)

USD 0.12B
S6EW:PA Ossiam Stoxx Europe 600 E.. 4.65 % 0.00 %

-0.60 (1.77%)

USD 0.12B
OSX6:XETRA Ossiam Stoxx Europe 600 E.. 4.65 % 0.00 %

-2.18 (1.77%)

USD 0.16B
S6EW:SW Ossiam STOXX® Europe 600.. 4.65 % 0.00 %

N/A

USD 0.12B
XCLN:CA iShares Global Clean Ener.. 4.31 % 0.00 %

-0.15 (1.77%)

CAD 9.02M
IQQH:XETRA iShares Global Clean Ener.. 4.30 % 0.00 %

+0.01 (+1.77%)

USD 3.34B
INRG:SW iShares Global Clean Ener.. 4.30 % 0.00 %

-0.03 (1.77%)

USD 2.41B
INRE:PA iShares Global Clean Ener.. 4.30 % 0.00 %

-0.02 (1.77%)

N/A
VCLN Virtus Duff & Phelps Clea.. 3.76 % 0.00 %

-0.50 (1.77%)

USD 4.98M
EUDV:PA SSgA SPDR ETFs Europe I P.. 3.75 % 0.00 %

-0.08 (1.77%)

USD 0.99B
SPYW:XETRA SPDR S&P Euro Dividend Ar.. 3.75 % 0.00 %

-0.05 (1.77%)

USD 0.97B
AMID Argent Mid Cap ETF 3.71 % 0.00 %

-0.02 (1.77%)

N/A
EUDV:SW SPDR® S&P Euro Dividend .. 3.48 % 0.00 %

-0.25 (1.77%)

N/A
EUDI:LSE SPDR® S&P Euro Dividend .. 3.43 % 0.00 %

-0.09 (1.77%)

USD 0.97B
EUDV:LSE SPDR® S&P Euro Dividend .. 3.43 % 0.00 %

-0.08 (1.77%)

USD 0.97B
FNRG:LSE Fidelity Clean Energy UCI.. 3.09 % 0.00 %

+0.04 (+1.77%)

USD 0.01B
SPYU:XETRA SPDR® MSCI Europe Utilit.. 2.96 % 0.00 %

N/A

USD 0.16B
UTIL:LSE SPDR® MSCI Europe Utilit.. 2.94 % 0.00 %

+0.05 (+1.77%)

USD 0.13B
STU:PA SPDR® MSCI Europe Utilit.. 2.94 % 0.00 %

+0.12 (+1.77%)

USD 0.13B
STUX:SW SPDR® MSCI Europe Utilit.. 2.94 % 0.00 %

-0.38 (1.77%)

USD 0.14B
ASRS:F BNP Paribas Easy ECPI Glo.. 2.91 % 0.00 %

-0.05 (1.77%)

N/A
HYDRO:PA BNP Paribas Easy ECPI Glo.. 2.91 % 0.00 %

+0.15 (+1.77%)

N/A
HYDUS:PA BNP Paribas Easy ECPI Glo.. 2.91 % 0.00 %

-0.07 (1.77%)

N/A
EMEC:XETRA BNP Paribas Easy ECPI Cir.. 2.27 % 0.00 %

+0.08 (+1.77%)

USD 0.62B
REUSE:PA BNP Paribas Easy ECPI Cir.. 2.27 % 0.00 %

+0.06 (+1.77%)

N/A
REUSD:PA BNP Paribas Easy ECPI Cir.. 2.27 % 0.00 %

-0.18 (1.77%)

N/A
QSML:AU VanEck MSCI International.. 1.45 % 0.00 %

-0.28 (1.77%)

N/A
LGGE:XETRA L&G Quality Equity Divide.. 1.12 % 0.00 %

-0.01 (1.77%)

USD 0.03B
ICLN iShares Global Clean Ener.. 0.00 % 0.46 %

-0.04 (1.77%)

USD 1.91B
RFG Invesco S&P MidCap 400® .. 0.00 % 0.35 %

-0.34 (1.77%)

N/A
INFR ClearBridge Sustainable I.. 0.00 % 0.47 %

-0.09 (1.77%)

USD 9.86M
JSMD Janus Henderson Small/Mid.. 0.00 % 0.50 %

-0.73 (1.77%)

USD 0.38B
SMLF iShares MSCI USA Small-Ca.. 0.00 % 0.30 %

-0.44 (1.77%)

N/A
INRG:LSE iShares Global Clean Ener.. 0.00 % 0.00 %

+1.25 (+1.77%)

N/A
S6EW:LSE Ossiam Stoxx Europe 600 E.. 0.00 % 0.00 %

-0.51 (1.77%)

N/A
JELS:LSE 0.00 % 0.00 %

N/A

N/A
IQQH:F iShares Global Clean Ener.. 0.00 % 0.00 %

-0.17 (1.77%)

N/A
OSX6:F Ossiam Lux - Ossiam Stoxx.. 0.00 % 0.00 %

-0.36 (1.77%)

N/A
SPYU:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

+0.58 (+1.77%)

N/A
SPYW:F SPDR S&P Euro Dividend Ar.. 0.00 % 0.00 %

+0.02 (+1.77%)

N/A
ZCLN:CA BMO Clean Energy Index ET.. 0.00 % 0.00 %

+0.06 (+1.77%)

CAD 0.06B
IBBJ 0.00 % 0.00 %

N/A

N/A
FCII:CA Franklin ClearBridge Sust.. 0.00 % 0.00 %

-0.33 (1.77%)

CAD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.08% 82% B 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.08% 82% B 70% C-
Trailing 12 Months  
Capital Gain 28.18% 74% C 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.18% 74% C 69% C-
Trailing 5 Years  
Capital Gain 397.85% 100% F 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 397.85% 100% F 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 44.90% 74% C 86% B+
Dividend Return 44.90% 74% C 86% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 39.87% 72% C 47% F
Risk Adjusted Return 112.61% 100% F 98% N/A
Market Capitalization 9.93B 89% A- 93% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.